Shares of Radius Health Inc (NASDAQ:RDUS) traded up 6.7% on Thursday . The stock traded as high as $36.93 and last traded at $36.12. 1,310,321 shares traded hands during mid-day trading, an increase of 35% from the average session volume of 967,825 shares. The stock had previously closed at $33.86.

Several analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 target price on shares of Radius Health in a report on Thursday. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Citigroup assumed coverage on Radius Health in a report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 target price for the company. Finally, ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $48.00.

The stock has a market cap of $1,620.00, a PE ratio of -6.65 and a beta of 1.10. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the previous year, the business earned ($1.07) EPS. equities analysts forecast that Radius Health Inc will post -5.57 earnings per share for the current year.

In related news, insider Jesper Hoiland purchased 6,800 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were purchased at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the transaction, the insider now directly owns 12,900 shares of the company’s stock, valued at approximately $374,616. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The stock was bought at an average price of $32.85 per share, for a total transaction of $1,642,500.00. Following the transaction, the insider now directly owns 5,548,799 shares in the company, valued at $182,278,047.15. The disclosure for this purchase can be found here. Insiders purchased a total of 158,578 shares of company stock worth $4,659,916 in the last 90 days. 15.00% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BB Biotech AG increased its position in Radius Health by 11.0% during the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after purchasing an additional 498,400 shares during the period. Farallon Capital Management LLC increased its position in Radius Health by 18.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after purchasing an additional 569,300 shares during the period. Vanguard Group Inc. increased its position in Radius Health by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after purchasing an additional 135,071 shares during the period. BlackRock Inc. increased its position in Radius Health by 10.0% during the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after purchasing an additional 262,896 shares during the period. Finally, State Street Corp increased its position in Radius Health by 12.9% during the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after purchasing an additional 213,399 shares during the period.

WARNING: “Radius Health (RDUS) Trading Up 6.7%” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/radius-health-rdus-trading-up-6-7/1812905.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.